These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18327319)

  • 1. de novo design and synthesis of N-benzylanilines as new candidates for VEGFR tyrosine kinase inhibitors.
    Uno M; Ban HS; Nabeyama W; Nakamura H
    Org Biomol Chem; 2008 Mar; 6(6):979-81. PubMed ID: 18327319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold.
    Shahin MI; Abou El Ella DA; Ismail NS; Abouzid KA
    Bioorg Chem; 2014 Oct; 56():16-26. PubMed ID: 24922538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction.
    Zhang Y; Liu H; Jiao Y; Yuan H; Wang F; Lu S; Yao S; Ke Z; Tai W; Jiang Y; Chen Y; Lu T
    Mol Divers; 2012 Nov; 16(4):787-802. PubMed ID: 23090418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
    Xi L; Zhang JQ; Liu ZC; Zhang JH; Yan JF; Jin Y; Lin J
    Org Biomol Chem; 2013 Jul; 11(26):4367-78. PubMed ID: 23715382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
    Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
    Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
    Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
    Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
    J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
    Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
    Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach.
    Liu YZ; Wang XL; Wang XY; Yu RL; Liu DQ; Kang CM
    J Mol Model; 2016 Sep; 22(9):222. PubMed ID: 27558799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
    J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
    Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
    Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation.
    Yan W; Huang Z; Wang Z; Cao S; Tong L; Zhang T; Wang C; Zhou L; Ding J; Luo C; Zhou J; Xie H; Duan W
    Chem Biol Drug Des; 2016 May; 87(5):694-703. PubMed ID: 26669707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and structure-activity relationships of novel insulin receptor tyrosine kinase activators.
    Lum RT; Cheng M; Cristobal CP; Goldfine ID; Evans JL; Keck JG; Macsata RW; Manchem VP; Matsumoto Y; Park SJ; Rao SS; Robinson L; Shi S; Spevak WR; Schow SR
    J Med Chem; 2008 Oct; 51(19):6173-87. PubMed ID: 18788731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of boswellic acid derivatives as potent VEGFR-2 inhibitors.
    Shen S; Xu X; Liu Z; Liu J; Hu L
    Bioorg Med Chem; 2015 May; 23(9):1982-93. PubMed ID: 25819335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.
    Wu Z; Fraley ME; Bilodeau MT; Kaufman ML; Tasber ES; Balitza AE; Hartman GD; Coll KE; Rickert K; Shipman J; Shi B; Sepp-Lorenzino L; Thomas KA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):909-12. PubMed ID: 15012992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis and Biological Evaluation of Uracil Derivatives as Novel VEGFR-2 Inhibitors.
    Liang J; Li X; Yang S; He X; Wang M; Meng F
    Curr Pharm Des; 2018; 24(6):734-740. PubMed ID: 29384056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.